Search Prime Grants

P30CA272302

Project Grant

Overview

Grant Description
University of Rochester Wilmot Cancer Institute Support Grant - The mission of the Wilmot Cancer Institute (WILMOT) at the University of Rochester (UR) is to provide the highest quality treatment and care, through expert and innovative medicine, science, and education, for any patient burdened by any cancer within Central and Western New York, and beyond.

WILMOT serves a distinct population in a catchment area of more than three million people confronted with a cancer incidence significantly above national averages, due to a disproportionately aging population, tobacco use, and predominantly poor urban and rural communities.

During a 50-year history, WILMOT’s research has led to changes in oncology standards of care and paradigm-shifting discoveries, including the science behind the HPV vaccine.

WILMOT investigators are respected internationally as leaders in cancer control and supportive care research, and WILMOT’s extraordinary expertise in this area has been recognized through a longstanding National Cancer Institute (NCI)-funded National Community Oncology Research Program research base award.

WILMOT also benefits from outstanding visibility and strength in hematological malignancy clinical and translational research.

WILMOT has created three transdisciplinary research programs (Genetics, Epigenetics and Metabolism; Cancer Microenvironment; and Cancer Prevention and Control), with a unifying research theme of “Aging and Cancer.”

WILMOT members continue to push the frontiers of cancer science: identifying bone marrow microenvironment characteristics that support myelodysplastic syndrome; defining the role of geriatric assessment in medical oncology; harnessing the innate immune system to attack pancreatic cancer; and discovering mediators of cancer resistance and novel cancer cell vulnerabilities with promise for therapeutic translation.

Attention to WILMOT’s 27-county catchment area through prevention services and research is achieved with bidirectional collaboration via a robust Community Cancer Action Council and associated research advisory committees.

Major institutional investments include space, senior scientists, junior faculty recruitment, and a clinical trial infrastructure resulting in WILMOT being a designated lead academic participating site of the National Clinical Trials Network.

With support of the UR, the community, and a P30 Cancer Center Support Grant, and under the leadership of Director Jonathan W. Friedberg, MD, MMSC (CM), WILMOT will:

1) Improve patient outcomes through paradigm-shifting, transdisciplinary discovery, integrating basic, translational, and population science;

2) Translate basic and population science discoveries to benefit patients through interventional clinical trials;

3) Enhance mentoring and career development in cancer science for researchers at all career stages, through interdisciplinary curricula and fostering an inclusive workforce culture; and

4) Engage communities in the Central and Western New York catchment area to uncover unmet needs and implement responsive cancer prevention, community-driven research, dissemination efforts, and education programs.

WILMOT conducts all of these activities with emphasis on diversity, equity, and inclusion, and guided by a strategic plan.
Funding Goals
TO PROVIDE AN ORGANIZATIONAL FOCUS AND STIMULUS FOR THE HIGHEST QUALITY CANCER RESEARCH THAT EFFECTIVELY PROMOTES INTERDISCIPLINARY CANCER RESEARCH AIMED TOWARD THE ULTIMATE GOAL OF REDUCING CANCER INCIDENCE, MORTALITY AND MORBIDITY. THE CANCER CENTER SUPPORT GRANT (CCSG) PROVIDES THE RESOURCES AND INFRASTRUCTURE TO FACILITATE THE COORDINATION OF INTERDISCIPLINARY PROGRAMS ACROSS A BROAD SPECTRUM OF RESEARCH FROM BASIC LABORATORY RESEARCH TO CLINICAL INVESTIGATION TO POPULATION SCIENCE. THE CCSG SUPPORTS SALARIES FOR SCIENTIFIC LEADERSHIP OF THE CENTER, SHARED RESOURCES FOR FUNDED CENTER INVESTIGATORS, CERTAIN ADMINISTRATIVE COSTS, PLANNING AND EVALUATION, AND DEVELOPMENTAL FUNDS FOR NEW RECRUITMENTS AND FEASIBILITY STUDIES.
Place of Performance
Rochester, New York 14642 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 107% from $2,075,744 to $4,301,002.
University Of Rochester was awarded Wilmot Cancer Institute Support Grant Project Grant P30CA272302 worth $4,301,002 from National Cancer Institute in March 2025 with work to be completed primarily in Rochester New York United States. The grant has a duration of 5 years and was awarded through assistance program 93.397 Cancer Centers Support Grants. The Project Grant was awarded through grant opportunity Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional).

Status
(Ongoing)

Last Modified 3/20/26

Period of Performance
3/15/25
Start Date
2/28/30
End Date
23.0% Complete

Funding Split
$4.3M
Federal Obligation
$0.0
Non-Federal Obligation
$4.3M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to P30CA272302

Transaction History

Modifications to P30CA272302

Additional Detail

Award ID FAIN
P30CA272302
SAI Number
P30CA272302-2148935167
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
F27KDXZMF9Y8
Awardee CAGE
03CZ7
Performance District
NY-25
Senators
Kirsten Gillibrand
Charles Schumer
Modified: 3/20/26